# Clinical trial results:
# A Multicentre Open-label Extension Study to Asses the Safety and Tolerability of LYC-30937-EC in Subjects with Active Ulcerative Colitis

## Summary

| | |
|---|---|
| EudraCT number | 2016-003633-26 |
| Trial protocol | NL HU CZ PL |
| Global end of trial date | 18 July 2018 |

**Results information**

| | |
|---|---|
| Result version number | v1 (current) |
| This version publication date | 08 April 2020 |
| First version publication date | 08 April 2020 |

## Trial information

**Trial identification**

| | |
|---|---|
| Sponsor protocol code | LYC-30937-2002 |

**Additional study identifiers**

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT02764229 |
| WHO universal trial number (UTN) | - |

Notes:

**Sponsors**

| | |
|---|---|
| Sponsor organisation name | Lycera Corp. |
| Sponsor organisation address | 620 W. Germantown Pike, Plymouth Meeting, PA, United States, 19462 |
| Public contact | Lycera Clinical Department, Lycera Corp., 001 6104575095, 30937_Clinical_Operations@Lycera.com |
| Scientific contact | Lycera Clinical Department, Lycera Corp., 001 6104575095, 30937_Clinical_Operations@Lycera.com |

Notes:

**Paediatric regulatory details**

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 28 December 2018 |
| Is this the analysis of the primary completion data? | No |

| | |
|---|---|
| Global end of trial reached? | Yes |
| Global end of trial date | 18 July 2018 |
| Was the trial ended prematurely? | Yes |

Notes:

## General information about the trial

Main objective of the trial:

The primary objective was to assess the safety and tolerability of LYC-30937-EC in participants with ulcerative colitis (UC).

Protection of trial subjects:

The study was conducted in full compliance with the principles of the "Declaration of Helsinki" (as amended in Tokyo, Venice, Hong Kong, and South Africa), International Council for Harmonisation (ICH) guidelines, and all of the applicable United States Code of Federal Regulations (CFR), 21 CFR Parts 50 & 312.

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 18 October 2016 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Netherlands: 3 |
| Country: Number of subjects enrolled | Poland: 76 |
| Country: Number of subjects enrolled | Czech Republic: 4 |
| Country: Number of subjects enrolled | Hungary: 2 |
| Country: Number of subjects enrolled | United States: 22 |
| Country: Number of subjects enrolled | Serbia: 5 |
| Worldwide total number of subjects | 112 |
| EEA total number of subjects | 85 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |

| | |
|---|---|
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 106 |
| From 65 to 84 years | 6 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details:

Participants were enrolled at 40 study centres in the United States, the Czech Republic, Hungary, Netherlands, Poland, and Serbia. Study centers included academic medical centres and non-academic medical clinics.

### Pre-assignment

Screening details:

Participant eligibility was determined at Week 8 of the double-blind study LYC-30937-2001 upon completion of the Week 8 study procedures. Eligible participants could immediately start their participation in this open-label extension study upon completion of the double-blind study.

### Period 1

| | |
|---|---|
| Period 1 title | Overall trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

### Arms

| | |
|---|---|
| **Arm title** | LYC-30937-EC 25 mg |

Arm description:

LYC-30937-EC was administered orally, once daily from Day 1 up to a total of 308 days of treatment (Week 44).

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | LYC-30937-EC |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Modified-release capsule, soft |
| Routes of administration | Oral use |

Dosage and administration details:

LYC 30937-EC 25 mg was administered once daily as a single delayed release, enteric coated hydroxylpropyl methyl cellulose capsule. Administration occurred in the morning upon awaking after fasting overnight. Participants should not have eaten for approximately 1 hour (or more) after taking study drug.

| **Number of subjects in period 1** | LYC-30937-EC 25 mg |
|---|---|
| Started | 112 |
| Completed | 10 |
| Not completed | 102 |
| Physician decision | 5 |
| Consent withdrawn by subject | 15 |
| Adverse event, non-fatal | 9 |
| Study terminated by sponsor | 69 |
| Lost to follow-up | 3 |
| Lack of efficacy | 1 |

## Baseline characteristics

| Reporting groups | |
|---|---|
| Reporting group title | LYC-30937-EC 25 mg |
| Reporting group description: | |
| LYC-30937-EC was administered orally, once daily from Day 1 up to a total of 308 days of treatment (Week 44). | |

| Reporting group values | LYC-30937-EC 25 mg | Total | |
|---|---|---|---|
| Number of subjects | 112 | 112 | |
| Age categorical<br>Units: Subjects | | | |
| Age continuous<br>Units: years | | | |
| arithmetic mean | 41.5 | | |
| full range (min-max) | 19 to 74 | - | |
| Gender categorical<br>Units: Subjects | | | |
| Female | 47 | 47 | |
| Male | 65 | 65 | |
| Ethnicity<br>Units: Subjects | | | |
| Hispanic or Latino | 4 | 4 | |
| Not Hispanic or Latino | 108 | 108 | |
| Race<br>Units: Subjects | | | |
| Asian | 1 | 1 | |
| Black or African American | 2 | 2 | |
| White | 109 | 109 | |

## End points

### End points reporting groups

| Reporting group title | LYC-30937-EC 25 mg |
|---|---|

Reporting group description:

LYC-30937-EC was administered orally, once daily from Day 1 up to a total of 308 days of treatment (Week 44).

### Primary: Summary of Treatment-Emergent Adverse Events (TEAEs)

| End point title | Summary of Treatment-Emergent Adverse Events (TEAEs)[1] |
|---|---|

End point description:

Defined by 21 CFR 312.32(a) and consistent with ICH E2A guidance, an AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. TEAEs were AEs that first occurred, or worsened, after the first dose of study drug and within 14 days after the permanent discontinuation of study drug. Related TEAE had a causality of suspected (possible or probable) or missing . Severe TEAE were Grade 3 TEAEs according to the National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) version 4.03. Serious TEAEs were AEs that at any dose resulted in death, was life threatening, required inpatient hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or other medically significant events that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the outcomes listed above.

| End point type | Primary |
|---|---|

End point timeframe:

TEAEs were collected from the time a participant received the first dose of study drug and within 14 days after the permanent discontinuation of study drug.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analysis was planned for this safety data.

| End point values | LYC-30937-EC 25 mg | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 111 | | | |
| Units: Number of participants | | | | |
| ≥ 1 TEAE | 56 | | | |
| ≥ 1 related TEAE | 12 | | | |
| ≥ 1 severe TEAE | 9 | | | |
| ≥ 1 serious TEAE | 6 | | | |
| ≥ 1 related serious TEAE | 1 | | | |
| ≥ 1 serious TEAE leading to death | 0 | | | |
| ≥ 1 TEAE leading to study drug withdrawn | 9 | | | |
| ≥ 1 TEAE leading to discontinuation from study | 9 | | | |
| ≥ 1 TEAE leading to dose interruption | 3 | | | |
| ≥ 1 serious TEAE leading to study drug withdrawn | 1 | | | |

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events (AEs) were collected from the time a participant signed the informed consent and completed participation in the preceding double-blind trial LYC-3097-2001, up to 46 weeks.

Adverse event reporting additional description:

Treatment-emergent AEs are AEs occurring or worsening after the first dose of study drug. AE severity was assessed by the Investigator using the NCI CTCAE v4.03.

'Subjects affected by non-serious adverse events' is the number of participants affected by non-serious AEs occurring at >5%.

| | |
|---|---|
| Assessment type | Systematic |

### Dictionary used

| | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 19.0 |

### Reporting groups

| | |
|---|---|
| Reporting group title | LYC-30937-EC 25 mg |

Reporting group description:

LYC-30937-EC was administered orally, once daily from Day 1 up to a total of 308 days of treatment (Week 44).

| Serious adverse events | LYC-30937-EC 25 mg | | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 6 / 111 (5.41%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | 0 | | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 1 / 111 (0.90%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal disorders | | | |
| Ulcerative colitis | | | |
| subjects affected / exposed | 2 / 111 (1.80%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pancreatitis acute | | | |
| subjects affected / exposed | 1 / 111 (0.90%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|---|---|---|---|
| Respiratory, thoracic and mediastinal disorders | | | |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 1 / 111 (0.90%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Anal abscess | | | |
| subjects affected / exposed | 1 / 111 (0.90%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 111 (0.90%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| **Non-serious adverse events** | LYC-30937-EC 25 mg | | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 14 / 111 (12.61%) | | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 7 / 111 (6.31%) | | |
| occurrences (all) | 9 | | |
| Gastrointestinal disorders | | | |
| Colitis ulcerative | | | |
| subjects affected / exposed | 11 / 111 (9.91%) | | |
| occurrences (all) | 15 | | |

## More information

## Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 23 August 2016 | Section 2.3.3: Information consolidated; Section 2.4: added Phase 1b study data and consolidated information; Section 4.4.1: Inclusion criterion 4 revised to require that women of child bearing potential use two highly effective forms of contraception; Section 6.2: added activity for site to telephone participants to remind them to complete diary; Sections 6.2 and 6.3: revised to define days at which participants should record stool frequency and rectal bleeding in their diary; Section 6.3.6: revised to state that study drug will be withheld in participants who exhibit any of the listed clinical laboratory elevations; Section 7.4: AE severity assessment revised to use NCI CTCAE grading; Section 7.5: revised to add sponsor medical monitor contact information and SAE reporting email and fax numbers; Section 7.11: revised to add individual stopping criteria based on abnormal echocardiogram findings of prolonged QT/QTc interval; Section 11.1: revised to remove statement that participants will be identified by their initials. Participant's initials are not being collected and therefore won't be used for participant identification. |
| 22 November 2016 | Section 1.0, 2.1, 2.2, 2.4: updated to include information on the Phase 1 study in patients with US who received LYC-30937-EC at single doses of 25 mg and 100 mg; Sections 1.0, 3.1.2, 3.2.2, 4.1, 4.5, 5.2, 6.1- 6.2.4, 7.6 and 8.4: revised due to extension of the open-label extension treatment period to up to 44 weeks, including the addition of study visits at Weeks 8, 20, 32, 44, and 46; Section 1.0: revised to add participating countries and to include the approximate last participant last visit timing date; Section 2.3.3: updated to include chronic toxicology information from rat and monkey studies; Section 4.4.1: Inclusion Criterion #2 revised to clarify that highly effective forms of contraception include hormonal contraceptives, which include the following forms oral, patch, long-acting injectable and implants; Section 4.5: revised to clarify that participants who withdraw should complete Visits 8 and 9; Section 5.3.3: revised to clarify that drug receipt is to be acknowledged in Interactive Web Response System upon receipt of drug; Sections 6.2 (Table 1 footnote), 6.2.1, 6.4.5,: updated to include body temperature log; Section 6.4.6: direction added to understand underlying baseline UC symptoms of abdominal pain and vomiting; Appendix A: revised the approximate blood volume collected. |

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

None reported